Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 15/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10081096 | 0.92 | PIK3CG (0.57) | PIK3CGPIK3CAPIK3CD | |
| SCHEMBL10081095 | 0.88 | PIK3CG (0.55) | PIK3CGPIK3CAPIK3CDNPC1RAB9A | |
| SCHEMBL10084973 | 0.86 | PIK3CD (0.57) | PIK3CGPIK3CAPIK3CD | |
| SCHEMBL10081097 | 0.83 | PIK3CG (0.51) | PIK3CGPIK3CAPIK3CDNPC1RAB9A | |
| SCHEMBL10081090 | 0.82 | PIK3CG (0.58) | PIK3CGPIK3CAPIK3CDNPC1RAB9A | |
| SCHEMBL12342693 | 0.82 | PIK3CG (0.49) | PIK3CGPIK3CAPIK3CDABL1 | |
| SCHEMBL10084742 | 0.80 | PIK3CD (0.58) | PIK3CGPIK3CAPIK3CD | |
| SCHEMBL10081159 | 0.79 | PIK3CG (0.64) | PIK3CGPIK3CANPC1RAB9AABL1 | |
| SCHEMBL10081099 | 0.78 | PIK3CG (0.46) | PIK3CGPIK3CAPIK3CDNPC1POLB | |
| SCHEMBL10081089 | 0.77 | PIK3CG (0.64) | PIK3CGPIK3CAPIK3CDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CG | PIK3CG 3/4885PIK3CA 1/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.